MX2020010878A - Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos. - Google Patents

Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.

Info

Publication number
MX2020010878A
MX2020010878A MX2020010878A MX2020010878A MX2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A MX 2020010878 A MX2020010878 A MX 2020010878A
Authority
MX
Mexico
Prior art keywords
making
methods
positive allosteric
allosteric modulator
modulator compounds
Prior art date
Application number
MX2020010878A
Other languages
English (en)
Inventor
Matthew Toczko
Jed Hubbs
Original Assignee
Neurocycle Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocycle Therapeutics Inc filed Critical Neurocycle Therapeutics Inc
Publication of MX2020010878A publication Critical patent/MX2020010878A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En el presente documento se describen polimorfos que comprenden 2',6-difluoro-5'-[3-(1-hidroxi-1-metiletil)-imidazo[1,2-b][1,2,4] triazin-7-il]bifenil-2-carbonitrilo (TPA023B) o sales del mismo. En un aspecto del presente documento se describe una sal polimórfica cristalina o cocristal de TPA023B con ácido fosfórico. En el presente documento también se describen métodos de preparación y uso de los mismos.
MX2020010878A 2018-04-18 2019-04-17 Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos. MX2020010878A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659226P 2018-04-18 2018-04-18
PCT/US2019/027880 WO2019204446A1 (en) 2018-04-18 2019-04-17 Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Publications (1)

Publication Number Publication Date
MX2020010878A true MX2020010878A (es) 2021-01-29

Family

ID=68239798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010878A MX2020010878A (es) 2018-04-18 2019-04-17 Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.

Country Status (14)

Country Link
US (2) US11542263B2 (es)
EP (1) EP3781566A4 (es)
JP (1) JP7449272B2 (es)
KR (1) KR20210011921A (es)
CN (1) CN112384513A (es)
AU (1) AU2019255282A1 (es)
BR (1) BR112020021104A2 (es)
CA (1) CA3096890A1 (es)
CL (1) CL2020002663A1 (es)
IL (1) IL278067A (es)
MX (1) MX2020010878A (es)
SG (1) SG11202010220QA (es)
TW (1) TW202012402A (es)
WO (1) WO2019204446A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
CA3154222A1 (en) * 2019-10-22 2021-04-29 Matthew TOCZKO Gabaa positive allosteric modulator compounds, methods of making, and uses thereof
JP2022554159A (ja) * 2019-10-23 2022-12-28 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ受容体モジュレーターによるてんかん状態の治療
US20210401849A1 (en) * 2020-06-30 2021-12-30 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
US6936608B2 (en) * 2000-11-10 2005-08-30 Merck Sharp & Dohme Ltd. Imidazo-triazine derivatives as ligands for GABA receptors
GB0117277D0 (en) * 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) * 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
SI2300455T1 (sl) * 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
WO2011011712A1 (en) * 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
MX2018009252A (es) * 2016-01-27 2019-01-21 Univ Zuerich Uso de moduladores de receptores de gabaa para el tratamiento de picor.
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用

Also Published As

Publication number Publication date
TW202012402A (zh) 2020-04-01
BR112020021104A2 (pt) 2021-02-23
JP7449272B2 (ja) 2024-03-13
SG11202010220QA (en) 2020-11-27
KR20210011921A (ko) 2021-02-02
JP2021522330A (ja) 2021-08-30
CA3096890A1 (en) 2019-10-24
CL2020002663A1 (es) 2021-06-11
IL278067A (en) 2020-11-30
US20210040103A1 (en) 2021-02-11
US20230139418A1 (en) 2023-05-04
WO2019204446A1 (en) 2019-10-24
EP3781566A1 (en) 2021-02-24
AU2019255282A1 (en) 2020-11-05
CN112384513A (zh) 2021-02-19
US11542263B2 (en) 2023-01-03
EP3781566A4 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
MX2020010878A (es) Compuestos moduladores alostericos positivos gabaa, metodos de preparacion y usos de los mismos.
SG11202111524YA (en) Process for the preparation of precursor compounds for lithium battery cathodes
PH12019550128A1 (en) Pyrrolo [1,2-b] pyridazine derivatives
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
TN2019000133A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
MX2019012927A (es) Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion.
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
BR112014032338A2 (pt) cristais de sal
BR112017001565A2 (pt) ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto?
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
MX2018004332A (es) Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas.
AU2017319080A1 (en) Pyrazolo[1,5-a]pyrimidine compound
CL2021000276A1 (es) Polimorfo cristalino del clorhidrato de 8-bromo-2-(1-metilpiperidin-4-ilamin)-4-(4-fenoxifenilamin)pirido[4,3-d]pirimidin-5(6h)-ona y método para prepararlo.
MX2022004642A (es) Compuestos moduladores alostericos positivos de gabaa, metodos de preparacion y usos de los mismos.
WO2015123519A8 (en) Preparation of 3,4-dihydro-1,4-benzoxazepin-5(2h)-one derivatives by cyclisation of 2-(am i no ethyloxy) benzoic acid derivatives
BR112014000085A2 (pt) derivados de ácido carboxílico com um anel oxazolo[4,5-c]piridina
MX2019007891A (es) Sales de oxalato de tianeptina y polimorfos.
MY164134A (en) Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
EA201291289A1 (ru) Кристаллическое производное тиенопиримидина
MX2016005173A (es) Un polimorfo estable de la sal de (2r)-4-oxo-4-[3-(trifluorometil) -5,6-dihidro[1,2,4]triazolo[4,3-a]pirazin-7(8h)-il]-1-(2,4,5-trif luorofenil)butan-2-amina con acido l-tartarico.
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
EA202190643A1 (ru) УЛУЧШЕННЫЙ СПОСОБ ПРОИЗВОДСТВА 3-[(1S)-1-ИМИДАЗО[1,2-a]ПИРИДИН-6-ИЛЭТИЛ]-5-(1-МЕТИЛПИРАЗОЛ-4-ИЛ)ТРИАЗОЛО[4,5-b]ПИРАЗИНА И ЕГО ПОЛИМОРФНЫХ ФОРМ
MX2020008066A (es) Formas de sal de compuesto organico.
CO2017002070A2 (es) Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina
PH12020551701A1 (en) Meglumine salts of thienopyrimidines